Biotechnology and pharmaceutical companies are increasingly moving away from transactional, small-batch synthesis in favor of integrated, end-to-end service partnerships. This transition is fueled by a growing pipeline of programs moving from preclinical research to commercial-scale production. Sponsors now prioritize CDMOs that offer comprehensive platforms covering synthesis, purification, and regulatory support to mitigate supply chain risks and ensure consistent quality across the entire development lifecycle.
Oligonucleotide CDMO Market Poised to Hit $11.14 Billion by 2031
The global market for oligonucleotide contract development and manufacturing is projected to surge to $11.14 billion by 2031, growing at a compound annual rate of 23.5%. This expansion, up from $3.88 billion in 2026, reflects a fundamental shift in how pharmaceutical firms outsource complex drug production.
North America currently leads the sector, controlling roughly 43.2% of the market share as of 2025. The region benefits from a dense concentration of biotech firms and established manufacturing infrastructure suited for antisense oligonucleotides and siRNA therapeutics. Market consolidation remains a defining feature, with the top five players—including Agilent Technologies, Bachem, and Thermo Fisher Scientific—holding over half of the global market. These firms are securing their positions through heavy capital investment, such as Agilent's $740 million commitment to scale commercial capacity, and strategic acquisitions aimed at integrating proprietary nucleic-acid technologies.
Comments (0)
No comments yet. Be the first!